Medifast (NYSE:MED) Issues Q4 2024 Earnings Guidance

Medifast (NYSE:MED) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.100-0.650 for the period, compared to the consensus estimate of -0.180. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.0 million.

Analyst Ratings Changes

Separately, DA Davidson upgraded shares of Medifast from an “underperform” rating to a “neutral” rating and upped their price target for the company from $16.50 to $17.00 in a research report on Tuesday.

Medifast Trading Up 1.2 %

NYSE:MED traded up $0.24 during trading hours on Thursday, reaching $19.94. 112,679 shares of the company traded hands, compared to its average volume of 389,757. The stock has a market capitalization of $218.14 million, a P/E ratio of 29.85 and a beta of 1.13. The business’s 50-day moving average price is $18.48 and its two-hundred day moving average price is $20.91. Medifast has a 1 year low of $17.07 and a 1 year high of $76.42.

Medifast (NYSE:MED) last posted its earnings results on Monday, November 4th. The specialty retailer reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.50. Medifast had a return on equity of 16.01% and a net margin of 1.09%. The business had revenue of $140.16 million during the quarter, compared to analyst estimates of $135.45 million. During the same quarter last year, the company earned $2.12 EPS. As a group, equities analysts anticipate that Medifast will post 1.12 EPS for the current year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.